Brought to you by 
MDRNA hopes to create RNAi leader through Cequent acquisition
30 Apr 2010
Executive Summary
MDRNA Inc. has acquired privately held Cequent Pharmaceuticals Inc., a fellow RNAi-focused company. MDRNA will issue shares worth $44mm to Cequent investors, plus an additional $2mm in stock to warrant and option holders. (Based on MDRNA's ten-day average prior to deal announced, it issued approximately 43.1mm shares.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com